Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.
Case of Postoperative Heart Attack Demonstrates How MG Can Complicate Cardiac Procedures
A patient with myasthenia gravis (MG) quickly deteriorated after he woke up from an endovascular procedure.
Read More
ADAMTS-13 Clearance Major Pathogenic Mechanism in iTTP
The findings suggest recombinant ADAMTS-13 may be a useful adjunct therapy to plasma exchange among patients who have thrombotic thrombocytopenic purpura (iTTP).
Anxiety, Depression, Suicidal Ideation Common Among College Students at Start of COVID-19 Pandemic
The study was designed and conducted by undergraduate researchers.
Case Report Highlights Hurdles in Identifying Pseudo-TTP
The patient’s thrombotic thrombocytopenic purpura (TTP)–like symptoms were caused by deficiencies of vitamins B1 and B12.
Case Report Highlights Rare Case of Tonsillar Merkel Cell Carcinoma
The patient sought care for a mass in her right buttock, but had no tonsillar symptoms.
iTTP Marked by Reversible Skin Microvascular Hyporeactivity, Study Finds
The impaired reactivity may play a role in organ injury, the authors suggested, among patients who have immune-mediated thrombotic thrombocytopenic purpura (iTTP).
New Insights Into Muscle-Specific Kinase Could Impact Myasthenia Gravis, Other Diseases
The new research could help identify ways to preserve neuromuscular junctions.
Multi-Hit TP53 Mutations Have Major Impact on Posttransplant Outcomes in MF
Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53.
“Rational” Approach to Caplacizumab Therapy in TTP Outlined in New Article
Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP).
Age of Onset an Important Clinical Factor in Triple-Negative MG
Female patients were most likely to experience onset of triple-negative myasthenia gravis (MG) between ages 0 to 9 years.
Nomogram Developed to Predict Risk of Myasthenic Crisis Following Thymectomy
The tool can help clinicians stratify patients into high-risk and low-risk categories.
Symptoms of Anxiety, PTSD Present Years After Acute iTTP, aHUS Episodes
New data underscore the long-term implications of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and atypical hemolytic-uremic syndrome (aHUS), both rare diseases.
Immunosuppressive Therapies, Comorbidities Heighten COVID-19 Risk in People With MPNs
Older age was also a risk factor for hospitalization and death in patients with myeloproliferative neoplasms (MPN) who contract COVID-19, the investigators found.
Surgery Has Significant HRQOL Implications for Children With Drug-Resistant Epilepsy
Investigators found that surgical intervention for epilepsy improves social functioning and increases the likelihood a patient will be free of seizures.
Sickle Cell Disease Cuts 20 Years From Life Expectancy, Study Finds
People with the inherited disease can expect to live 52.6 years following birth, the report shows.
Risk of Second Malignancies Not Elevated Among Older MPN Patients Treated With Hydroxyurea
The risk of second malignancy was similar among patients aged 66 and older who were treated with and without hydroxyurea.
Race, Ethnicity May Not Affect Biologic Prescribing Patterns for Psoriasis
Dermatologists recommended biologics at similar rates in scenarios describing Black, Hispanic, and White patients with moderate to severe psoriasis.
Case Report Shows Ocular MG, Autoimmune Encephalitis Can Coexist
The patient received a diagnosis of myasthenia gravis (MG), then underwent a medical odyssey as physicians attempted to pin down the cause of his neurological symptoms.
Validation Study Affirms Prognostic Value of MITS in TTP
Investigators said the Mortality in TTP Score (MITS) was effective at characterizing the risk of death in patients hospitalized with thrombotic thrombocytopenic purpura (TTP).
Biomarkers May Predict Treatment Response in Steroid-Refractory/Dependent GVHD
Lower levels of certain biomarkers were predictive of treatment response for graft-versus-host disease (GVHD) at day 28, investigators found.
AChR Antibody Titers May Help Predict Conversion to Generalized Myasthenia Gravis
The new report suggests patients with acetylcholine receptor (AChR) antibody titers above 8.11 nmol/L were at higher risk of conversion.
Accurate Remote Assessment of Psoriasis Possible From Patient Photographs, Questionnaire Responses, Study Finds
In this new analysis, investigators found significant agreement between in-person and remote assessments.
Treatment of Rare Anemias Shifting Rapidly
Investigators said several new anemia therapies are in development, and many of them may help wide swaths of patients.
Ruxolitinib Reduces Posttransplant GVHD Risk in Pediatric β-Thalassemia Major
Patients who had ruxolitinib added to their prophylactic regimens had lower rates of acute and chronic graft-versus-host disease (GVHD).
Study: MuSK-Specific Antibodies Do Not Explain Variation in Serum IgG4 Levels in People With MuSK MG
People with muscle-specific kinase myasthenia gravis appear to have more active antibody responses in general, the study found.
JAK2 Mutations Rare, With Unclear Implications in MDS
A new report found only about 2.8% of people with myelodysplastic syndromes (MDS) have JAK2 mutations.
New WHO Biosimilar Guidelines Aim to Streamline, Clarify Regulations
The new recommendations from the World Health Organization (WHO) urge viewing the totality of evidence when evaluating biosimilar products.
Predicting Post-AlloSCT Outcomes in Myelofibrosis
The EASIX scoring system should not be used to predict outcomes following allogeneic stem cell transplantation (alloSCT) in patients with myelofibrosis.
Opioid Prescription Decision Tool May Be Feasible Option to Curb Overprescribing
A feasibility study shows many providers intended to continue using the tool, although some said they did not have sufficient time or did not need the tool.
Polygenic Risk Scores Predict Cancer Cases, but Not Aggressiveness in Prostate Cancer
The new report found polygenic risk scores likely will not help identify patients at highest risk.